Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and atogepant, strategies for prevention of cluster headaches, and the use of anti-calcitonin gene-related peptide monoclonal antibodies in migraine.
Questions:
- What has been the effect of the COVID-19 pandemic on young people with headaches, and has this led to over-medication during the pandemic? (00:22)
- For people who have had unsuccessful prior treatment, eptinezumab appears to improve patient-reported outcomes; how can physicians use these findings in routine practice? (01:45)
- Long-term safety and tolerability data for atogepant in the prevention of migraine were discussed in your session; how do you interpret these findings? (02:30)
- What insight into the prevention of cluster headaches emerged from your session at EAN 2022? (03:27)
- How could symptom severity correlate with response to anti-calcitonin gene-related peptide monoclonal antibodies in migraine, and could this be used to predict treatment efficacy? (04:31)
The ePoster session titled Headache 1 took place at the European Academy of Neurology Congress 2022, 25–28 June 2022.
Disclosure: Raquel Gil-Gouveia has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of EAN 2022.
